- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pfizer Inc. DRC (PFEm)
Buenos Aires
Currency in ARS
7,010.00
+50.00(+0.72%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6,630.00
7,080.00
52 wk Range
5,990.00
10,450.00
Pfizer DRC (BCBA:PFEm) Annual Report
This summary provides an overview of the most significant critical numbers from each of the Pfizer DRC financial reports, including the Pfizer Inc. DRC income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.
Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the BCBA:PFEm financials over time via breakdowns of their annual reports. Advanced annual reports and additional financial summaries (including visual charts) are available to users with an InvestingPro account.
Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the BCBA:PFEm financials over time via breakdowns of their annual reports. Advanced annual reports and additional financial summaries (including visual charts) are available to users with an InvestingPro account.
Key Ratios
Statements Highlights
| Period Ending: | 2015 31/12 | 2016 31/12 | 2017 31/12 | 2018 31/12 | 2019 31/12 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 41,651 | 81,288 | 101,175 | 59,554 | 63,627 | |
Gross Profit | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 33,266 | 50,602 | 67,078 | 41,765 | 47,207 | |
Operating Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 9,791 | 26,980 | 39,841 | 12,517 | 16,328 | |
Net Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 9,159 | 21,979 | 31,372 | 2,119 | 8,031 | |
Total Assets | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 154,229 | 181,476 | 197,205 | 226,501 | 213,396 | |
Total Current Liabilities | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 25,920 | 42,671 | 42,138 | 47,794 | 42,995 | |
Total Equity | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 63,473 | 77,463 | 95,917 | 89,288 | 88,497 | |
Levered Free Cash Flow | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 10,760.75 | 30,939.63 | 25,484.88 | 5,560.5 | 12,777.13 | |
Cash from Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 14,403 | 32,580 | 29,267 | 8,700 | 12,744 | |
Cash from Investing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -4,271 | -22,546 | -15,783 | -32,278 | 2,652 | |
Cash from Financing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -9,649 | -9,816 | -14,834 | 26,066 | -17,140 | |
Net Change in Cash | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 475 | 159 | -1,515 | 2,449 | -1,810 | |
* In Millions of USD (except for per share items)
FAQ
What were Pfizer DRC's earnings for the latest quarter?
The Pfizer DRC EPS (TTM) is 1.39. Pfizer DRC reported sales of 13,715.00, net income of 2,967.00, and EPS of 0.52 for the latest quarter.
What was Pfizer DRC's net income for the latest quarter?
Pfizer DRC's net income for the latest quarter was 2,967.00.
How did Pfizer DRC's performance compare year-over-year in the latest quarter?
The company's revenue moved from 17,764.00 in the previous quarter to 13,715.00 in the latest quarter, and net income moved from 410.00 to 2,967.00 compared to the previous quarter.
What is Pfizer DRC's net profit margin on a TTM basis?
Pfizer DRC's trailing twelve months (TTM) net profit margin is 12.62%.
How does Pfizer DRC's debt to equity ratio compare to industry standards?
Pfizer DRC's total debt-to-equity ratio is 68.84%.
What is Pfizer DRC's return on investment on a TTM basis?
Pfizer DRC's trailing twelve months (TTM) return on investment (ROI) is 8.62%.
Did Pfizer DRC gain or lose cash last quarter?
In the latest quarter, Pfizer DRC's net change in cash was 374.00 million.
What were Pfizer DRC's total assets and liabilities in the latest quarter?
As of the latest quarter, Pfizer DRC reported total assets of 208,028.00 million and total liabilities of 36,452.00 million.
How has Pfizer DRC's total revenue grown this year?
Pfizer DRC's total revenue was 17,764.00 in the previous quarter and 13,715.00 in the latest quarter.
What is Pfizer DRC's gross margin on a TTM basis?
Pfizer DRC's trailing twelve months (TTM) gross margin is 74.42%.
What was Pfizer DRC's revenue per share for the latest quarter?
Pfizer DRC's revenue per share for the latest quarter was 37.08.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.